The Manufacturers Life Insurance Company Purchases 811 Shares of Flexion Therapeutics, Inc. (FLXN)

The Manufacturers Life Insurance Company grew its position in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 3.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,802 shares of the specialty pharmaceutical company’s stock after buying an additional 811 shares during the period. The Manufacturers Life Insurance Company owned 0.07% of Flexion Therapeutics worth $441,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of FLXN. Bank of New York Mellon Corp lifted its holdings in Flexion Therapeutics by 27.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock worth $54,921,000 after purchasing an additional 591,981 shares in the last quarter. Capital World Investors lifted its holdings in Flexion Therapeutics by 2.0% during the 2nd quarter. Capital World Investors now owns 2,538,000 shares of the specialty pharmaceutical company’s stock worth $51,318,000 after purchasing an additional 49,000 shares in the last quarter. State Street Corp lifted its holdings in Flexion Therapeutics by 66.3% during the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock worth $27,888,000 after purchasing an additional 549,948 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Flexion Therapeutics by 5.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock worth $21,321,000 after purchasing an additional 59,143 shares in the last quarter. Finally, Schroder Investment Management Group lifted its holdings in Flexion Therapeutics by 29.3% during the 2nd quarter. Schroder Investment Management Group now owns 509,427 shares of the specialty pharmaceutical company’s stock worth $10,474,000 after purchasing an additional 115,413 shares in the last quarter. 68.95% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $44.00 price objective on shares of Flexion Therapeutics in a report on Thursday, August 10th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Finally, ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Flexion Therapeutics currently has a consensus rating of “Buy” and an average target price of $98.33.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) opened at $26.32 on Monday. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93. Flexion Therapeutics, Inc. has a one year low of $15.96 and a one year high of $32.25.

In other Flexion Therapeutics news, insider Michael D. Clayman bought 5,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were acquired at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the purchase, the insider now directly owns 35,395 shares of the company’s stock, valued at $835,322. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Yamo Deniz bought 3,000 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was acquired at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the purchase, the insider now directly owns 5,000 shares in the company, valued at $120,750. The disclosure for this purchase can be found here. Insiders acquired a total of 13,075 shares of company stock worth $315,698 over the last 90 days. Corporate insiders own 15.98% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “The Manufacturers Life Insurance Company Purchases 811 Shares of Flexion Therapeutics, Inc. (FLXN)” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://transcriptdaily.com/2017/11/27/the-manufacturers-life-insurance-company-purchases-811-shares-of-flexion-therapeutics-inc-flxn.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply